Clinical research in febrile neutropenia in cancer patients: Past achievements and perspectives for the future

Figure 1 Algorithm to decide primary prophylactic granulocyte colony-stimulating factor usage. Adapted from European Organization for Research and Treatment of Cancer Guidelines. Data taken from[13]. FN: Febrile neutropenia; G-CSF: Granulocyte colony-stimulating factor.

Figure 2 Relationship between the occurrence of febrile neutropenia and the severity of granulocytopenia.

Figure 3 Decision tree for the administration of antibiotic therapy to low-risk patients with febrile nerutropenia. N: Nausea; V: Vomiting; D: Diarrhea; P. aeruginosa: Pseudomonas aeruginosa.

Figure 4 Decision tree for administration of antibiotics to high-risk patients with febrile neutropenia. ESKAPE: E. coli, S. aureus, Klebsiella sp. Acinetobacter sp, P. aeruginosa, Enterococcus sp; ESBL: Extended-spectrum β-lactamase; MRSA: Methicillin-resistant S. aureus; VRE: Vancomycin-resistant enterococci; HSCT: Hematopoietic stem cell transplant patients; P. aeruginosa: Pseudomonas aeruginosa.